Androgen Receptor Signaling Inhibition in Advanced Castration Resistance Prostate Cancer: What Is Expected for the...

Area of Science:

• Oncology
• Pharmacology

Background:

• The androgen signaling pathway is crucial for treating advanced prostate cancer.
• Resistance to current anti-androgen drugs is a significant clinical challenge, limiting treatment efficacy.
• Understanding resistance mechanisms is vital for developing new therapeutic strategies.

Purpose of the Study:

• To review the current status of androgen inhibition in advanced prostate cancer treatment.
• To summarize known mechanisms of resistance to available anti-androgen drugs.
• To provide an overview of current and future research for overcoming androgen receptor (AR) inhibition resistance.

Main Methods:

• Literature review of studies on androgen signaling pathway, prostate cancer, and anti-androgen therapies.
• Analysis of mechanisms of primary and acquired resistance to androgen deprivation therapies.
• Comprehensive overview of ongoing and future research directions in AR inhibition.

Main Results:

• Resistance to androgen signaling pathway inhibitors is a major obstacle in advanced prostate cancer management.
• Multiple resistance mechanisms, including AR gene amplification and mutations, are identified.
• Combination therapies and novel anti-androgen drugs are emerging as promising strategies.

Conclusions:

• Androgen receptor inhibition remains a cornerstone in advanced prostate cancer therapy.
• Overcoming resistance through novel therapeutic approaches is critical for improving patient outcomes.
• Future research focuses on combination strategies and next-generation AR inhibitors to address treatment resistance.